

Pr OPDIVO®-BASED REGIMENS FOR:



**Neoadjuvant, resectable
non-small cell lung cancer
(NSCLC)**

OPDIVO
(nivolumab)

+ platinum-doublet chemotherapy

OPDIVO, in combination with platinum-doublet chemotherapy, is indicated for the neoadjuvant treatment of adult patients with resectable NSCLC (tumours ≥ 4 cm or node positive).

- Positive associations were observed between the level of PD-L1 expression and advanced disease stage, and the magnitude of the treatment benefit.



**Previously untreated
metastatic non-small cell
lung cancer (NSCLC)**

OPDIVO + Pr **YERVOY**
(nivolumab) (ipilimumab)
**+ 2 cycles of
platinum-doublet chemotherapy**

OPDIVO, in combination with ipilimumab and 2 cycles of platinum-doublet chemotherapy, is indicated for the treatment of adult patients with metastatic NSCLC with no EGFR or ALK genomic tumor aberrations, and no prior systemic therapy for metastatic NSCLC.




**Previously untreated,
unresectable malignant
pleural mesothelioma
(MPM)**

OPDIVO + Pr **YERVOY**
(nivolumab) (ipilimumab)

OPDIVO, in combination with ipilimumab, is indicated for the treatment of adult patients with unresectable malignant pleural mesothelioma who have not received prior systemic therapy for MPM.



+ platinum-doublet chemotherapy




Neoadjuvant Treatment of Resectable NSCLC

In the neoadjuvant treatment of resectable **NSCLC** for tumours ≥ 4 cm or node positive.¹

OPDIVO (360 mg) Q3W
and 3 cycles of platinum-doublet chemotherapy Q3W

360
mg

Platinum-doublet chemotherapy



NSCLC: non-small cell lung cancer.

Adapted from Product Monograph¹

OPDIVO
(nivolumab)



YERVOY
(ipilimumab)

+ 2 cycles of
platinum-doublet
chemotherapy




Previously Untreated Metastatic NSCLC

In metastatic **NSCLC** with no EGFR or ALK mutations:¹

OPDIVO (360 mg) Q3W + YERVOY (1 mg/kg) Q6W
and 2 cycles of platinum-doublet chemotherapy Q3W


360
mg

1
mg/kg



ALK: anaplastic lymphoma kinase; EGFR: epidermal growth factor receptor; NSCLC: non-small cell lung cancer.

Adapted from Product Monograph¹




Previously Untreated MPM

In unresectable **MPM** with no prior systemic therapy for MPM:¹



OPDIVO (360 mg) Q3W + YERVOY (1 mg/kg) Q6W




MPM: malignant pleural mesothelioma.

Adapted from Product Monograph¹

OR



OPDIVO (3 mg/kg) Q2W + YERVOY (1 mg/kg) Q6W



Adapted from Product Monograph¹

[CLICK HERE](#)
to find out more about OPDIVO.

OPDIVO
(nivolumab)

+ platinum-doublet
chemotherapy

OPDIVO + **Pr YERVOY**
(nivolumab) (ipilimumab)

+ 2 cycles of
platinum-doublet chemotherapy

OPDIVO + **Pr YERVOY**
(nivolumab) (ipilimumab)

Please consult the [OPDIVO Product Monograph](#) and the [YERVOY Product Monograph](#) for indications, contraindications, warnings, precautions, adverse reactions, interactions, dosing, and conditions of clinical use.
The Product Monograph is also available by calling us at: 1-866-463-6267.

Reference: 1. OPDIVO Product Monograph. Bristol-Myers Squibb Canada Co.

OPDIVO and YERVOY and the OPDIVO and YERVOY logos are registered trademarks of Bristol-Myers Squibb Company used under license by Bristol-Myers Squibb Canada Co.